一、英文文章:

1.          Trimble EL, Rajaraman PL, Chao A, Gross T, Levin C, Qiao YL, Rebbeck T, Stevens L, Zhao FH. Need for National Commitments to Cancer Research to Guide Public Health Investment and Practice. In: Cancer: Disease Control Priorities, Third Edition (Volume 3). Edited by Gelband H, Jha P, Sankaranarayanan R, Horton S. Washington (DC): The International Bank for Reconstruction and Development / The World Bank © 2015 International Bank for Reconstruction and Development / The World Bank.; 2015. doi: 10.1596/978-1-4648-0349-9_ch15.

2.          Wang SM, Hu SY, Chen W, Chen F, Zhao FH, He W, Ma XM, Zhang YQ, Wang J, Sivasubramaniam P et al. Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening. BMC cancer. 2015, 15:848. doi: 10.1186/s12885-015-1882-9.

3.          Katki HA, Zhao FH, Hu SY, Zhang Q, Qiao YL, Schiffman M. Reply to Letter: Using novel risk stratification statistics to better understand the value of screening tests. International journal of cancer. 2016, 139(7):1669. doi: 10.1002/ijc.30192.

4.          Liu YJ, Zhang Q, Hu SY, Zhao FH. Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. BMC cancer. 2016, 16:164. doi: 10.1186/s12885-016-2207-3.

5.          Valdez M, Jeronimo J, Bansil P, Qiao YL, Zhao FH, Chen W, Zhang X, Kang LN, Paul P, Bai P et al. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china. International journal of cancer. 2016, 138(6):1453-1461. doi: 10.1002/ijc.29877.

6.          Yu LL, Kang LN, Zhao FH, Lei XQ, Qin Y, Wu ZN, Wang H, Chen W, Qiao YL. Elevated Expression of Human Papillomavirus-16/18 E6 Oncoprotein Associates with Persistence of Viral Infection: A 3-Year Prospective Study in China. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016, 25(7):1167-1174. doi: 10.1158/1055-9965.Epi-15-1057.

7.          Zhang Q, Liu YJ, Hu SY, Zhao FH. Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China. BMC cancer. 2016, 16(1):848. doi: 10.1186/s12885-016-2893-x.

8.          Zhao FH, Hu SY, Zhang Q, Zhang X, Pan QJ, Zhang WH, Gage JC, Wentzensen N, Castle PE, Qiao YL et al. Risk assessment to guide cervical screening strategies in a large Chinese population. International journal of cancer. 2016, 138(11):2639-2647. doi: 10.1002/ijc.30012.

9.          Dong L, Feng RM, Zhang L, Xu XQ, Zhao XL, Wang MZ, Qiao YL, Zhao FH. Prospective comparison of hybrid capture 2 and SPF??-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China. Journal of gynecologic oncology. 2017, 28(5):e66. doi: 10.3802/jgo.2017.28.e66.

10.        Dong L, Hu SY, Zhang Q, Feng RM, Zhang L, Zhao XL, Zhang X, Qiao YL, Zhao FH. Risk Prediction of Cervical Cancer and Precancers by Type-Specific Human Papillomavirus: Evidence from a Population-Based Cohort Study in China. Cancer prevention research (Philadelphia, Pa). 2017, 10(12):745-751. doi: 10.1158/1940-6207.Capr-17-0088.

11.        Feng RM, Hu SY, Zhao FH, Zhang R, Zhang X, Wallach AI, Qiao YL. Role of active and passive smoking in high-risk human papillomavirus infection and cervical intraepithelial neoplasia grade 2 or worse. Journal of gynecologic oncology. 2017, 28(5):e47. doi: 10.3802/jgo.2017.28.e47.

12.        Holt HK, Zhang L, Zhao FH, Hu SY, Zhao XL, Zhang X, Pan QJ, Zhang WH, Smith JS, Qiao YL. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China. International journal of cancer. 2017, 140(3):544-554. doi: 10.1002/ijc.30468.

13.        Hu SY, Zhang WH, Li SM, Li N, Huang MN, Pan QJ, Zhang X, Han Y, Zhao FH, Chen W et al. Pooled analysis on the necessity of random 4-quadrant cervical biopsies and endocervical curettage in women with positive screening but negative colposcopy. Medicine. 2017, 96(17):e6689. doi: 10.1097/md.0000000000006689.

14.        Song Y, Zhao YQ, Li L, Pan QJ, Li N, Zhao FH, Chen W, Zhang X, Qiao YL. A retrospective analysis of the utility of endocervical curettage in screening population. Oncotarget. 2017, 8(30):50141-50147. doi: 10.18632/oncotarget.15658.

15.        Zhao XL, Hu SY, Zhang Q, Dong L, Feng RM, Han R, Zhao FH. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. Journal of gynecologic oncology. 2017, 28(4):e30. doi: 10.3802/jgo.2017.28.e30.

16.        Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer medicine. 2017, 6(1):12-25. doi: 10.1002/cam4.869.

17.        Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N et al. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study. Annals of internal medicine. 2018, 168(1):20-29. doi: 10.7326/m17-1609.

18.        Dong L, Wang MZ, Zhao XL, Feng RM, Hu SY, Zhang Q, Smith JS, Qiao YL, Zhao FH. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. Gynecologic oncology. 2018, 148(1):103-110. doi: 10.1016/j.ygyno.2017.11.016.

19.        Feng RM, M ZW, Smith JS, Dong L, Chen F, Pan QJ, Zhang X, Qiao YL, Zhao FH. Risk of high-risk human papillomavirus infection and cervical precancerous lesions with past or current trichomonas infection: a pooled analysis of 25,054 women in rural China. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2018, 99-100:84-90. doi: 10.1016/j.jcv.2017.12.015.

20.        Rezhake R, Hu SY, Zhao YQ, Zhang L, Zhao XL, Dominguez AZ, Qiao YL, Zhou CH, Zhao FH. Impact of International Collaborative Training Programs on Medical Students' Research Ability. Journal of cancer education : the official journal of the American Association for Cancer Education. 2018, 33(3):511-516. doi: 10.1007/s13187-016-1134-y.

21.        Zhang L, Xu XQ, Hu SY, Chen F, Zhang X, Pan QJ, Zhang WH, Feng RM, Dong L, Zhang Q et al. Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China. Gynecologic oncology. 2018, 151(2):221-228. doi: 10.1016/j.ygyno.2018.09.012.

22.        Rezhake R, Hu SY, Zhao S, Xu XQ, Zhao XL, Zhang L, Wang Y, Zhang X, Pan QJ, Qiao YL et al. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women. International journal of cancer. 2019, 144(1):34-42. doi: 10.1002/ijc.31633.

23.        Rezhake R, Xu XQ, Montigny S, Berger A, Hu SY, Liu ZH, Sankaranarayanan R, Qiao YL, Basu P, Zhao FH. Training Future Leaders: Experience from China-ASEAN Cancer Control Training Program. Journal of cancer education : the official journal of the American Association for Cancer Education. 2019, 34(6):1067-1073. doi: 10.1007/s13187-018-1409-6.

24.        Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer medicine. 2019, 8(14):6195-6211. doi: 10.1002/cam4.2399.

25.        Aballéa S, Beck E, Cheng X, Demarteau N, Li X, Ma F, Neine M, Zhao FH. Risk factors for cervical cancer in women in China: A meta-model. Women's health (London, England). 2020, 16:1745506520940875. doi: 10.1177/1745506520940875.

26.        Dong L, Zhang L, Hu SY, Feng RM, Zhao XL, Zhang Q, Pan QJ, Zhang X, Qiao YL, Zhao FH. Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study. Clinical epigenetics. 2020, 12(1):62. doi: 10.1186/s13148-020-00853-1.

27.        Hu SY, Rezhake R, Chen F, Zhang X, Pan QJ, Ma JF, Qiao YL, Zhao FH. Outcomes in women with biopsy-confirmed cervical intraepithelial neoplasia grade 1 or normal cervix and related cofactors: A 15-year population-based cohort study from China. Gynecologic oncology. 2020, 156(3):616-623. doi: 10.1016/j.ygyno.2019.12.027.

28.        Hu SY, Tsang SH, Chen F, Pan QJ, Zhang WH, Hong Y, Sampson JN, Hildesheim A, Zhao FH, Kreimer AR. Association between Common Vaginal Infections and Cervical Non-HPV16/18 Infection in HPV-Vaccinated Women. The Journal of infectious diseases. 2020. doi: 10.1093/infdis/jiaa384.

29.        Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ et al. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. Journal of the National Cancer Institute. 2020, 112(2):145-153. doi: 10.1093/jnci/djz074.

30.        Rezhake R, Chen F, Hu SY, Zhao XL, Zhang X, Cao J, Qiao YL, Zhao FH, Arbyn M. Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China. International journal of cancer. 2020, 147(8):2053-2064. doi: 10.1002/ijc.33001.

31.        Zhao XL, Liu ZH, Zhao S, Hu SY, Muwonge R, Duan XZ, Du LJ, Su CF, Xiang XE, Zhang X et al. Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China. International journal of cancer. 2020. doi: 10.1002/ijc.33290.

32.        Zhao XL, Xu XQ, Duan XZ, Rezhake R, Hu SY, Wang Y, Xia CF, Zhang X, Qiao YL, Sankaranarayanan R et al. Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: A population-based study in rural China. International journal of cancer. 2020, 147(5):1275-1285. doi: 10.1002/ijc.32881.

二、中文文章:

[1] 李雨聪, 张莉, 胡尚英, 赵方辉, 乔友林, 李少林. 高危型人乳头瘤病毒检测初筛宫颈癌后几种分流方法的效果评价 [J]. 肿瘤, 2015, 35(05): 536-4.

[2] 马俊飞, 赵雪莲, 张莉, 向喜娥, 王素梅, 邱丽芝, 张倩, 胡尚英, 赵方辉. 2006—2009年山西省襄垣县VIA/VILI筛查宫颈癌的检出效果评价 [J]. 癌症进展, 2015, 13(06): 637-41.

[3] 赵宇倩, 宋艳, 赵方辉, 章文华, 李凌, 陈凤, 陈汶, 潘秦镜, 沈贵华, 乔友林. 阴道镜下四象限活检在宫颈癌前病变筛查中的价值 [J]. 中华肿瘤杂志, 2015, 37(11): 875-9.

[4] 赵宇倩, 赵方辉, 胡尚英, 陈汶, 陈凤, 崔剑锋, 刘彬, 章文华, 张询, 潘秦镜, 乔友林. 中国女性人群宫颈人乳头瘤病毒感染及型别分布的多中心横断面研究 [J]. 中华流行病学杂志, 2015, 36(12): 1351-6.

[5] 郑凤仙, 孙小伟, 李彩红, 高国旗, 赵宇倩, 赵方辉, 李晓莉, 张丽霞, 李长卿, 刘金红, 胡巧芝, 于爱敏. 河南省新密市2010~2013年农村女性宫颈癌筛查结果分析 [J]. 中国肿瘤, 2015, 24(12): 1007-11.

[6] 苏采峰, 刘妞, 张倩, 向喜娥, 李志霞, 马俊飞, 史少东, 胡尚英, 赵方辉. 山西省襄垣县采用careHPV检测技术进行宫颈癌初筛的效果分析 [J]. 中国肿瘤, 2016, 25(08): 608-11.

[7] 孙小伟, 郑凤仙, 刘金红, 赵方辉, 张丽霞, 宋艳, 乔友林. 国产HPV杂交捕获技术在农村宫颈癌筛查中的应用 [J]. 中华肿瘤防治杂志, 2016, 23(03): 137-41.

[8] 孙小伟, 郑凤仙, 赵方辉, 刘金红, 王晶, 张倩, 钱金鹏, 胡巧枝, 于爱敏, 宋俊霞, 高银存, 牛彩霞, 李彩红. 两种方法筛查子宫颈癌的效果分析 [J]. 中国妇幼保健, 2016, 31(17): 3635-8.

[9] 张莉, 冯瑞梅, 胡尚英, 张倩, 赵雪莲, 热米拉·热扎克, 陈凤, 张询, 潘秦镜, 赵方辉, 乔友林. 细胞学检测为非典型鳞状细胞且人乳头瘤病毒阴性妇女的宫颈癌患病风险评估 [J]. 中华流行病学杂志, 2016, 37(06): 801-4.

[10] 张倩, 胡尚英, 冯瑞梅, 董丽, 陈凤, 张询, 潘秦镜, 马俊飞, 史少东, 赵方辉, 乔友林. 高危型人乳头瘤病毒感染变化与宫颈癌及癌前病变发病风险的15年前瞻队列随访研究 [J]. 中华肿瘤杂志, 2016, 38(10): 792-7.

[11] 党乐, 马俊飞, 郭董平, 李八一, 苏采峰, 赵宇倩, 冯瑞梅, 张询, 潘秦镜, 胡尚英, 赵方辉, 乔友林. 我国农村地区宫颈癌筛查中人乳头瘤病毒检测阳性女性的分流策略 [J]. 中国肿瘤临床与康复, 2017, 24(03): 257-61.

[12] 董丽, 胡尚英, 张倩, 冯瑞梅, 张莉, 赵雪莲, 马俊飞, 史少东, 张询, 潘秦镜, 章文华, 乔友林, 赵方辉. 山西省宫颈癌筛查队列中人乳头瘤病毒基因型别分布10年动态变化规律研究 [J]. 中华流行病学杂志, 2017, 38(01): 20-5.

[13] 何美, 杜佳, 赵方辉, 雷海科, 张艳, 李蓉, 周琦, 邱惠. 城市女性宫颈癌机会性筛查接受障碍原因及影响因素 [J]. 中国公共卫生, 2017, 33(08): 1166-9.

[14] 胡尚英, 热米拉·热扎克, 张倩, 董丽, 陈凤, 张询, 潘秦镜, 章文华, 马俊飞, 乔友林, 赵方辉. HPV16/18 DNA分型对宫颈细胞学ASC-US女性的风险分层管理作用研究 [J]. 肿瘤学杂志, 2017, 23(09): 780-4.

[15] 魏丽惠, 沈丹华, 赵方辉, 耿力, 毕蕙, 赵昀, 徐海苗, 李静然, 吕卫国, 王悦. 中国子宫颈癌筛查及异常管理相关问题专家共识(二) [J]. 中国妇产科临床杂志, 2017, 18(03): 286-8.

[16] 魏丽惠, 赵昀, 沈丹华, 赵方辉, 耿力, 毕蕙, 徐海苗, 李静然. 中国子宫颈癌筛查及异常管理相关问题专家共识(一) [J]. 中国妇产科临床杂志, 2017, 18(02): 190-2.

[17] 赵方辉. 注射HPV疫苗利大于弊 [J]. 中国食品药品监管, 2017, (09): 76.

[18] 赵方辉, 张莉. 新时代下的肿瘤预防研究 [J]. 中华预防医学杂志, 2017, 51(08): 665-6.

[19] 富诗岚, 余艳琴, 徐慧芳, 胡尚英, 乔友林, 赵方辉. 中国大陆人群对人乳头瘤病毒预防性疫苗的认知和态度 [J]. 中国肿瘤临床, 2018, 45(23): 1220-4.

[20] 刘植华, 林威, 王月云, 吴波, 袁世新, 姚吉龙, 赵晓山, 陈斌, 乔友林, 赵方辉, 陈汶, 胡尚英. 高危型人乳头状瘤病毒风险分层在深圳地区人乳头状瘤病毒初筛阳性人群分流中的应用 [J]. 中华肿瘤杂志, 2018, 40(10): 757-63.

[21] 热米拉·热扎克, 朱之恺, 张倩, 徐小倩, 韦梦娜, 胡尚英, 王岩, 张莉, 赵雪莲, 乔友林, 赵方辉. 不同介质标本中人乳头瘤病毒E6癌蛋白检测效果对比研究 [J]. 病毒学报, 2018, 34(05): 549-54.

[22] 陶思源, 彭介入, 王英, 张桂婷, 陈志余, 赵霏, 马剑桥, 杨雪, 乔友林, 赵方辉, 杨春霞. 子宫颈癌及癌前病变患者直接经济负担及其影响因素研究 [J]. 中华预防医学杂志, 2018, 52(12): 1281-6.

[23] 王月云, 林威, 吴波, 袁世新, 姚吉龙, 赵晓山, 陈斌, 乔友林, 赵方辉, 陈汶, 胡尚英, 刘植华. 2014—2016年深圳市子宫颈癌筛查中HPV阳性者HPV高危亚型分布及相关因素 [J]. 中华预防医学杂志, 2018, 52(05): 480-5.

[24] 徐小倩, 张莉, 胡尚英, 热米拉·热扎克, 赵雪莲, 陈凤, 张询, 潘秦镜, 乔友林, 赵方辉. HPV载量在阴道镜下随机活检中的作用分析 [J]. 中华预防医学杂志, 2018, 52(05): 475-9.

[25] 余艳琴, 贾萌萌, 郝金奇, 富诗岚, 徐慧芳, 赵方辉, 胡尚英, 范金虎, 乔友林. 中国女性三阴性乳腺癌发病相关因素的Meta分析 [J]. 中国肿瘤, 2018, 27(11): 881-8.

[26] 张爱爱, 党乐, 何涛, 刘多丽, 高春翔, 常挨厚, 刘美清, 张红梅, 段仙芝, 张莉, 赵方辉, 乔友林. 汉族和蒙古族女性宫颈癌筛查认知意愿和疫苗接受度调查 [J]. 中国肿瘤临床与康复, 2018, 25(10): 1153-8.

[27] 张莉, 李佳瑶, 热米拉·热扎克, 胡尚英, 徐小倩, 赵雪莲, 赵爽, 胡芳芳, 陈凤, 张询, 乔友林, 赵方辉. hrHPV DNA载量 分型和E6蛋白对宫颈癌前病变进展的预测作用 [J]. 中国肿瘤临床, 2018, 45(17): 878-82.

[28] 张莉, 热米拉·热扎克, 胡尚英, 赵雪莲, 徐小倩, 富诗岚, 马俊飞, 任红梅, 赵方辉. 山西省襄垣县农村妇女和基层医务人员对宫颈癌及其筛查的认知和评价 [J]. 中国妇幼卫生杂志, 2018, 9(02): 1-5 9.

[29] 张莉, 赵方辉. 预防性人乳头状瘤病毒疫苗的应用研究进展 [J]. 中华肿瘤杂志, 2018, 40(10): 724-8.

[30] 赵爽, 赵方辉.  HPV治疗性疫苗研究进展 [J]. 中华预防医学杂志, 2018, 52(05): 556-60.

[31] 赵雪莲, 热米拉·热扎克, 胡尚英, 张莉, 徐小倩, 陈凤, 潘秦镜, 张询, 赵方辉. 高危型HPV DNA单独检测及与薄层液基细胞学联合筛查对宫颈癌及宫颈高度病变的筛查效果比较 [J]. 中华预防医学杂志, 2018, 52(05): 469-74.

[32] 彭介入, 陶思源, 温莹, 杨雪, 马剑桥, 赵霏, 陈志余, 张桂婷, 乔友林, 赵方辉, 杨春霞. 中国城镇地区子宫颈癌筛查的卫生经济学评价 [J]. 中华肿瘤杂志, 2019, (02): 154-60.

[33] 乔友林, 赵方辉. 首个国产子宫颈癌疫苗获批上市，售价仅为同种进口疫苗的一半 [J]. 抗癌之窗, 2019, (06): 6-7.

[34] 王华庆, 王岩, 王朝华, 王亚敏, 孙晓冬, 许涤沙, 李明珠, 李燕, 李智, 余文周, 余艳琴, 岳晨妍, 张小松, 郭欣, 胡尚英, 赵方辉, 赵超, 赵昀, 秦冉, 夏昌发. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识(简版) [J]. 中国病毒病杂志, 2019, 9(06): 401-18.

[35] 王华庆, 王岩, 王朝华, 王亚敏, 孙晓冬, 许涤沙, 李明珠, 李燕, 李智, 余文周, 余艳琴, 岳晨妍, 张小松, 郭欣, 胡尚英, 赵方辉, 赵超, 赵昀, 秦冉, 夏昌发. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识（简版） [J]. 中国疫苗和免疫, 2019, 25(06): 718-35.

[36] 王玉莹, 王兆京, 张瑜, 高晓虹, 杨春霞, 赵方辉, 乔友林, 马莉, 郎景和. 中国农村15种子宫颈癌筛查方案的卫生经济学评价 [J]. 中华妇产科杂志, 2019, (12): 840-7.

[37] 余艳琴, 富诗岚, 徐慧芳, 韦梦娜, 陈琦, 胡尚英, 赵方辉, 乔友林. 中国大陆女性体检人群中人乳头瘤病毒型别感染率及九价疫苗中HPV各型别分布的系统评价 [J]. 肿瘤预防与治疗, 2019, 32(02): 103-13.

[38] 张莉, 热米拉·热扎克, 胡尚英, 董丽, 赵爽, 赵雪莲, 徐小倩, 潘秦镜, 张询, 乔友林, 赵方辉. 阴道镜结果正常或低度病变妇女发生宫颈癌前病变的前瞻性风险分层研究 [J]. 中国肿瘤临床, 2019, 46(15): 768-72.

[39] 赵方辉, 张莉. 预防性人类乳头瘤病毒疫苗开启了宫颈癌的全面防控时代 [J]. 中华预防医学杂志, 2019, (01): 10-2.

[40] 赵爽, 赵雪莲, 胡尚英, 王岩, 热米拉·热扎克, 徐小倩, 段仙芝, 陈凤, 张询, 赵方辉. 汉族和蒙古族女性HPV感染率及型别分布的差异分析 [J]. 中华流行病学杂志, 2019, (11): 1439-44.

[41] 韦梦娜, 余艳琴, 徐慧芳, 富诗岚, 胡尚英, 赵方辉, 乔友林. 中国大陆地区不同宫颈病变人群中人乳头瘤病毒感染率及型别分布的系统研究 [J]. 中国肿瘤临床与康复, 2020, 27(02): 133-7.

[42] 徐慧芳, 余艳琴, 邵晨轶, 张询, 胡尚英, 赵方辉, 乔友林. DH3与cobas4800在宫颈癌筛查中的效果对比研究 [J]. 中国肿瘤临床与康复, 2020, 27(02): 129-32.

[43] 张韶凯, 赵方辉, 乔友林. 中国宫颈癌防治研究20年历程与成就 [J]. 中华流行病学杂志, 2020, 41(06): 809-12.

三、会议论文：

 ADDIN EN.REFLIST 1.          Zou HC, Wang W, Ma YY, Wang YJ, Zhao FH, Wang SM, Zhang SK, Ma W. How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China. Human Vaccines Immunother. 2016, 12(1):39-46. doi: 10.1080/21645515.2015.1072667.

2.          Basu P, Meheus F, Chami Y, Hariprasad R, Zhao FH, Sankaranarayanan R. Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings. Int J Gynecol Obstet. 2017, 138:26-32. doi: 10.1002/ijgo.12183.

3.          Wang M, Hu SY, Zhao S, Zhang WH, Pan QJ, Zhang X, Chen F, Han JX, Ma JF, Smith JS et al. Accuracy of triage strategies for human papillomavirus DNA-positive women in low-resource settings: A cross-sectional study in China. Chin J Cancer Res. 2017, 29(6):496- . doi: 10.21147/j.issn.1000-9604.2017.06.04.

4.          Zhang Q, Dong L, Hu SY, Feng RM, Zhang X, Pan QJ, Ma JF, Zhang L, Zhao XL, Sankaranarayanan R et al. Risk stratification and long- term risk prediction of E6 oncoprotein in a prospective screening cohort in China. Int J Cancer. 2017, 141(6):1110-1119. doi: 10.1002/ijc.30807.

5.          Han LL, Husaiyin SLY, Zhao FH, Rezhake RML, Niyazi MY. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or with Abnormal Thin-Prep Cytology Test Results. Clin Lab. 2018, 64(9):1363-1371. doi: 10.7754/Clin.Lab.2018.180138.

6.          Xue L, Hu WQ, Zhang HM, Xie ZL, Zhang X, Zhao FH, Qiao YL, Gao LJ, Ma W. Awareness of and willingness to be vaccinated by human papillomavirus vaccine among junior middle school students in Jinan, China. Human Vaccines Immunother. 2018, 14(2):404-411. doi: 10.1080/21645515.2017.1393132.

7.          Zhao FH. Risk stratified screening and management for cervical cancer. Cancer Sci. 2018, 109:729-729. doi:

8.          Ma L, Wang YY, Gao XH, Dai Y, Zhang Y, Wang ZJ, Wang XX, Wang LM, Jiang J, Jing XH et al. Economic evaluation of cervical cancer screening strategies in urban China. Chin J Cancer Res. 2019, 31(6):974-983. doi: 10.21147/j.issn.1000-9604.2019.06.13.

9.          Xia CF, Hu SY, Xu XQ, Zhao XL, Qiao YL, Broutet N, Canfell K, Hutubessy R, Zhao FH. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. Lancet Public Health. 2019, 4(9):E462-E472. doi: 10.1016/s2468-2667(19)30162-8.

10.        Xu HF, Yu YQ, George W, Smith JS, Hu SY, Dang L, Zhang X, Pan QJ, Qiao YL, Zhao FH. Comparison of the performance of paired urine and cervical samples for cervical cancer screening in screening population. J Med Virol. 2019:7. doi: 10.1002/jmv.25597.

11.        Zhao FH, Qiao YL. Cervical cancer prevention in China: a key to cancer control. Lancet. 2019, 393(10175):969-970. doi: 10.1016/s0140-6736(18)32849-6.

12.        Zhao S, Zhao XL, Hu SY, Lu J, Duan XZ, Zhang X, Chen F, Zhao FH. Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China. Chin J Cancer Res. 2019, 31(4):663-672. doi: 10.21147/j.issn.1000-9604.2019.04.10.

13.        Zhao XL, Zhao S, Hu SY, Zhao K, Zhang Q, Zhang X, Pan QJ, Zhao FH. Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China. J Infect Dis. 2019, 219(2):215-222. doi: 10.1093/infdis/jiy507.

14.        Duan RF, Qiao YL, Clifford G, Zhao FH. Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. Cancer Med. 2020, 9(1):374-384. doi: 10.1002/cam4.2697.

15.        Zhang SK, Zhao FH. Comment on "Will HPV vaccination prevent cervical cancer". BMC Med. 2020, 18(1):3. doi: 10.1186/s12916-020-01589-8.

16.        Zhao YQ, Zhao FH, Hu SY, Zhang XN, Zhang WH, Pan QJ, Gage JC, Sankaranarayanan R, Qiao YL. Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chin J Cancer Res. 2020, 32(3):383- . doi: 10.21147/j.issn.1000-9604.2020.03.09.

[1]   胡尚英, 冯瑞梅, 赵方辉, 陈凤, 乔友林. 主动、被动吸烟与人乳头瘤病毒感染和宫颈高度癌前病变的关系:一项多中心以人群为基础的横断面研究; 全国肿瘤流行病学和肿瘤病因学学术会议, 中国四川成都, F, 2015 [C].

[2]   孙小伟, 赵方辉, 赵宇倩, 李彩红, 郑凤仙, 李晓莉, 张丽霞, 刘金红, 乔友林. 国产HPV核酸检测(DH2)在农村地区宫颈癌筛查中的应用; 全国肿瘤流行病学和肿瘤病因学学术会议, 中国四川成都, F, 2015 [C].

[3]   张莉, 冯瑞梅, 胡尚英, 张倩, 赵雪莲, 热米拉.热扎克, 陈凤, 张询, 潘秦镜, 赵方辉, 乔友林. 宫颈癌筛查轻度异常妇女的患病风险评价; 全国肿瘤流行病学和肿瘤病因学学术会议, 中国四川成都, F, 2015 [C].

[4]   张倩, 冯瑞梅, 胡尚英, 马俊飞, 陈凤, 李志霞, 赵方辉, 乔友林. 山西宫颈癌筛查队列妇女高危HPV感染率的15年变化分析; 全国肿瘤流行病学和肿瘤病因学学术会议, 中国四川成都, F, 2015 [C].

[5]   赵雪莲, 马俊飞, 张莉, 向喜娥, 王素梅, 邱丽芝, 张倩, 胡尚英, 赵方辉. 2006-2009年山西省襄垣县VIA/VILI筛查宫颈癌的临床效果评价; 全国肿瘤流行病学和肿瘤病因学学术会议, 中国四川成都, F, 2015 [C].

[6]   赵宇倩, 陈凤, 赵方辉, 胡尚英, 张询, 郑凤仙, 乔友林. careHPV在农村基层应用的可行性研究; 全国肿瘤流行病学和肿瘤病因学学术会议, 中国四川成都, F, 2015 [C].